f4aa57d8-df4c-4fee-979a-0f981c8762da
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 71
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.470
- INTERFERON_ALPHA_RESPONSE+0.420
- FATTY_ACID_METABOLISM+0.350
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.330
- BILE_ACID_METABOLISM+0.320
- MYC_TARGETS_V2+0.310
- XENOBIOTIC_METABOLISM+0.310
- PEROXISOME+0.290
- PANCREAS_BETA_CELLS+0.260
- P53_PATHWAY+0.240
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.600
- ANGIOGENESIS-0.490
- UV_RESPONSE_DN-0.290
- INFLAMMATORY_RESPONSE-0.280
- MYOGENESIS-0.270
- NOTCH_SIGNALING-0.230
- KRAS_SIGNALING_UP-0.210
- COAGULATION-0.200
- APICAL_JUNCTION-0.190
- HEDGEHOG_SIGNALING-0.190
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 4769f22f-eeaf-4108-9555-55cc5d6ae27b | — | — | 0.859 |
| 2 | ee24b470-4509-4687-a91e-6d2b967336b9 | — | — | 0.814 |
| 3 | 2d83a9e6-da2d-47e1-b2e7-4b07b108f7bd | — | — | 0.775 |
| 4 | TCGA-CV-5439-01A-01R-1686-07 | — | — | 0.762 |
| 5 | b2b4cc41-5760-4463-bcde-16115ceb12c2 | — | — | 0.751 |
| 6 | AUR-ADCB-TTM1-A-1-1-R-A742-41 | — | C | 0.748 |
| 7 | TCGA-C8-A133-01A-32R-A12D-07 | — | B | 0.748 |
| 8 | 7a458b19-1b7c-422c-b900-cd77e5009421 | — | — | 0.748 |
| 9 | db087000-74fa-4044-812f-01842b99f448 | — | — | 0.724 |
| 10 | A0DA6087-9D43-41F9-8569-9F9320E4A9E8 | — | — | 0.723 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.470 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.420 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.350 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.330 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.320 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.310 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.310 | Inavolisib | — uncovered |
| PEROXISOME | 0.290 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.260 | Cobimetinib | — uncovered |
| P53_PATHWAY | 0.240 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.230 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.220 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.190 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.180 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.180 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.180 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.170 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.140 | Temsirolimus | — uncovered |
| MYC_TARGETS_V1 | 0.140 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.110 | Inavolisib | — uncovered |